SCIENION US, Inc. Receives ISO 13485 Certification
News Mar 20, 2015
SCIENION US, Inc has announced that its entire portfolio of microarray services is now manufactured under ISO 13485 certification, an internationally recognized standard for quality management systems (QMS). The certification is accredited by TÜV SÜD America Inc.
ISO 13485:2003 specifies requirements for a quality management system where an organization needs to demonstrate its ability to provide medical devices and related services that consistently meet customer requirements and regulatory requirements applicable to medical devices and related services.
"SCIENION had already earned a global reputation for producing very high quality spots, always emphasizing quality in every step of our manufacturing process. Today, we're very pleased to be adding the external validation of our ISO 13485-compliant Quality Management System," said Dr. Claude Dufresne, SCIENION US, Inc President and Chief Business Officer.
"As the leading provider of microarray-based services for a wide variety of applications, we remain committed to our customers in providing the highest quality of products and services in this market," said Holger Eickhoff, SCIENION CEO. "We believe that SCIENION is now in a stronger position to take the next step with our customers pursuing regulatory clearance of microarray-based testing platforms in the Diagnostics Market."
SCIENION’s microarray services at the SCIENION AG facilities have been manufactured in compliance with the ISO 9001:2008 standard since December 2008.
Back in 2009, researchers identified a herd of Awassi sheep suffering from "day blindness". As that term implies, these sheep were blind during the day (in bright light) but could see at night, in low-light conditions. After identifying the genetic basis of this blindness, researchers have now successfully used gene therapy to restore their daytime vision.READ MORE
The National Institutes of Health announced the launch of a new initiative to help speed the development of cures for sickle cell disease. The Cure Sickle Cell Initiative will take advantage of the latest genetic discoveries and technological advances to move the most promising genetic-based curative therapies safely into clinical trials within five to 10 years.